Kwon Byung-se, utility representative, met with correspondents at the Plaza Hotel in Jung-gu, Seoul on the 16th.
Utrex is a biotechnology company that is developing drugs for inflexible diseases such as cancer through immunotherapy using immune system & # 39; which protect viruses and toxins in the human body. The mission statement, Utrex, also showed the intention to develop new immunotherapeutic drugs such as EU & # 39; (new), & # 39; IT & # 39; (immune therapy) and LEX & # 39; (method).
Immunotoxicant treats cancer cells with a normal immune system or strengthens a weakened immune system in several ways to get rid of cancer cells. Compared to conventional anti-cancer drugs or drug target drugs that attack specific cancer cells, they are less resistant to drugs and are safe from side effects such as leukopenia and hair loss. According to GBI Research, the market for immunotherapy drugs is expected to grow at an average annual rate of 23.9% of 18 trillion earned in 2015 to 86 trillion earned in 2022.
◇ Immunology Research & Hanwoo & # 39; … Original technology acquired for immunotherapy
Kwon Byung-seh, who established Utilities in February 2015, is an immunology authority, who has been working on selling kangwoo products. He was a chemistry and bioscience professor at Ulsan University and head of the National Cancer Center Immunosochemistry Division at Yale University. Kwon said, "The study of immunology over the past 40 years has led to the development of differential immunotherapy."
In particular, first noticed in 1989 when the 4-1BB receptor, which triggered T & # 39; is associated with the immune modulation antibody drug. T, immune cells, assault and destroy cancer cells. 4-1BB can selectively function or reduce immune function to operate T. cells Utrex uses this to separate and grow T cells from the blood of cancer patients and then spray them into the patient's body.
(EBViNT cells), which treat lymphoma, laryngeal cancer, stomach cancer, etc., is one-stage tumor, glioblastoma / malignant that is ½ phase treatment, non-small-cell cell lung cancer and breast cancer. Cell WTiNT, which treats glioma, etc., in step one. "Aptity Cell will end in the second phase of the clinical trials by 2020," he said. "It aims to be licensed by the US Food and Drug Administration (FDA) in 2022 by designating innovative medicines."
In addition, T-treatment expresses an antimic container antigen & # 39; (CAR-T) that improves the anti-cancer effect by introducing a gene that successfully detects and destroys cancer cells in T cells (CAR) The CAR-T therapeutic agent Exposure has caused side effects such as cytokin syndrome that attacks normal cells unfavorable and causes hypotension and acute renal damage. However, CAR-T Utility Therapeutics reduced the adverse effects by simply attacking the malignant cells, targeting HDL-DRs, antigen expressed when normal cells were changed to malign cells. By moderating production and standardization of products, the cost of the drug, which has reached hundreds of hundreds of thousands gained, has decreased significantly. Other drugs such as EU101 and EU102, active in the treatment of cancer cells by implementing the T cell immune response, are being developed.
These new development drugs are also looking for technology exports. Kwon said, "There are many technologies that we have now, but it's all impossible to develop them all." He said, "We will raise clinical costs through technology exports and work with global pharmaceutical companies to build success stories."
◇ New drug development in the United States, such as the bridge head … Aspiration Big Big Pharma & # 39;
Kwon's top priority is to establish a bridge in the US and Europe for the development of new drugs. In September, we signed a Memorandum of Understanding (UDM) with the US JGBLI (JG Business Link International) and ABB Anti-Cell to successfully access the USA. JGBLI will support research and development centers (Research and Development) in the United States and will consult with the Maryland Pharmacy College in order to approve anti-cancer drugs. "This is the first step in clinical trials for T cell therapy in the United States," said Kwon. "We will continue to endeavor to license unoccupied drugs, starting with App VientiCell."
The KOSDAQ listing for clinical funding is also ahead. On December 15 he passed the Korean Exchange preliminary screening and confirmed the planned 27.6 billion amount earned to win 36.4 billion. He said, "The purpose of the list is to ensure that managers are transparent and contribute to the growth of the company," he said. "From year 2022 to the year of the launch of technology products and exports, etc. Growing through 2013," We will achieve our vision. "